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Introduction
MicroRNAs (miRNAs) are short, noncoding RNAs that act as endogenous triggers of the RNAi pathway. The founding miRNA, lin-4, was discovered over 20 years ago in the nematode Caenorhabditis elegans (1, 2) . More recently a large number of miRNA genes have been identified in a range of organisms. There are currently 462 human miRNAs listed in the Sanger database, and many more are predicted to exist (3) . miRNAs biogenesis begins with a primary transcript that is generated by RNA polymerase II (see (4) for a review). Sequential processing events by the ribonuclease III enzymes Drosha and Dicer yield the mature miRNA species (see Figure 1) . Averaging 22 nucleotides long, the mature miRNA is loaded into the RNA induced silencing complex (RISC) where it directs translational suppression of target mRNAs. Several computational algorithms have been developed with the goal of defining the networks of genes regulated by miRNAs (see (5) for a review). While the exact list of targets is not defined, the predicted targets extend to genes involved in myriad cellular processes. It is estimated that 30% of the genome is under miRNA post-transcriptional regulation.
Despite the large number of candidate targets, the exact cellular pathways that are regulated by miRNAs are only beginning to be understood, particularly in mammals. miRNAs have been implicated in muscle development, hematopoietic differentiation, insulin regulation, and cell proliferation and apoptosis (see (6) 
for a review).
Ongoing studies by a number of research groups have demonstrated extensive alterations in miRNA expression in human cancer (7) . One common alteration is elevated expression of the polycistronic miR-17-92. This polycistronic cluster is comprised of miR-17, miR-18, miR-19a, miR-20a, miR-19b, and miR-92. We recently reported that this cluster of miRNAs can cooperate with c-Myc in a mouse model for lymphomagenesis (8) . This miRNA cluster has also been implicated in colorectal carcinoma and lung carcinoma (9, 10) . Expression of miR-17-92 is high in proliferating cells, and is regulated in part by c-Myc itself (11) .
We hypothesize that inhibition of the microRNAs within this cluster is a therapeutic approach for the treatment of breast cancer. We tested this hypothesis using several approaches, described below.
Body

Task 1. Introduction of miRNA inhibitors and mimics into breast carcinoma lines.
The goal of this Task was to develop strategies for inhibition of function of miRNAs within the miR-17-92 polycistron. We hypothesized that this would prove to be cytotoxic due to the cell's dependence on the oncogenic miRNAs. We followed two general approaches. The first approach was direct inhibition of mature miRNAs using modified antisense RNAs (12, 13, 14) . Two nucleic acid modification chemistries were tested. The first was the well established 2'-O-methyl modification on the ribose ring. This modification renders the oligonucleotide resistant to nuclease degradation, and provides a small increase in hybridization energy with complementary RNAs. The second modification was a locked nucleic acid (LNA) ribose backbone. This is a methylene bridge between the 2' and 4' carbons on the ribose. This locks the conformation of the ribose ring, enhancing hybridization energy significantly. These oligonucleotides are also resistant to nuclease degradation. Both modifications are commercially available.
We designed antisense oligonucleotides against miR-18, miR-19b, miR-20a, and miR-92, using both chemistries. These oligonucleotides were transfected into a panel of cell lines, including breast carcinoma, to test their affects on cell viability. Viability was determined using the Celltiterglo reagent, which measures mitochondrial activity and is an indirect measurement of cell number and cell viability.
Initial work focused on 2'-O-methyl modified inhibitors (see Figure 2 ). Inhibitors were transfected individually and in combination into a panel of cell lines, at 100 nM final concentration. Viability assays indicated that the carcinoma cell lines Hela and HCT-116, and the hemangioma line SVEC4-10 were sensitive to inhibition of all miRNAs within miR-17-92. An inhibitor to let-7 was used as a control, since this miRNA is decreased in cancer and is not expected to essential for growth. Control (no oligo) transfections were also done. Interestingly, the breast carcinoma cell line MDA-435 was not sensitive to inhibition of miR-17-92 miRNAs.
To test the effects of differing chemistries we also tested LNA based oligonucleotide inhibitors for cytotoxicity in Hela cells. We first performed a dose-response curve to determine the most effective concentration. As shown in Figure 3 , LNA inhibitors are much more effective against Hela cells, with cytotoxic effects as low as 3 nM. Unfortunately, the Let-7 control inhibitor also exhibited cytotoxicity, suggesting this chemistry leads to non-specific toxicity due to unknown mechanisms. Nevertheless, at 3 nM the miR-20 LNA inhibitor did have specificity. This finding was extended with a time-course study. Cytotoxicity was measured at 24, 48 and 72 hours post-transfection (see Figure 4) . As in the dose-response, miR-20 inhibitors lead to consistent cytotoxicity, peaking at 72 hours post-transfection. Inhibition of other miRNAs did not lead to reproducible toxicity.
The optimal conditions for miR-20 inhibition led to 50% reduction in viability when using the LNA modification, which was much less than that observed using the 2'-Omethyl modification (77%, Figure 2 ). In addition, the lack of cytoxicity with LNA inhibitors against miR-19 or miR-92, which was seen using 2'-O-methyl modified oligonucleotides, suggests that this general approach suffers from non-specific toxicity of unknown mechanism.
To develop an alternate strategy we investigated the primary transcript of miR-17-92. We hypothesized that we could use established antisense strategies to inhibit transcription or processing of this primary transcript. First we needed to characterize the transcriptional start site of miR-17-92. We identified the core promoter region, including the initiator sequence and TATA box, and uncovered a regulatory step via E2F transcription factors. This is detailed in the attached manuscript. Our current research is directed at using antisense RNAs to interfere with this primary transcript. Task 2. miRNA intervention as a cancer therapeutic. The overall goal of this Task was to combine miRNA inhibitors with classic small molecule chemotherapeutics to test for enhanced cytotoxicity in breast carcinoma cells lines.
Due to non-specific toxicity of miRNA inhibitors we are currently pursing this Task using antisense inhibitors to the primary transcript. These studies are ongoing.
Key Research Accomplishments.
• Tested a range of miRNA inhibitors using two different ribose modification chemistries • Uncovered non-specific toxicity issues with LNA modified antisense oligonucleotides • Defined core promoter region for miR-17-92, including initiator and TATA box • Uncovered regulatory pathway from E2F transcription factors to miR-17-92
Reportable Outcomes
Publications: 
Conclusion
We have found that LNA oligonucleotide inhibitors have non-specific toxicity of unknown mechanism. It may be preferable to target the miRNA primary transcript with conventional antisense molecules. We are currently testing this. It is becoming clear that non-coding RNAs play an important role in the regulation of cell function and can contribute to human disease. One group of non-coding RNAs that has generated much recent attention is miRNAs. 3 These small RNAs have widespread impact on gene expression via the RNA interference pathway. The founding miRNA, lin-4, was discovered over 20 years ago in the nematode Caenorhabditis elegans (1, 2). More recently a large number of miRNA genes have been identified in a range of organisms. There are currently 474 human miRNAs listed in the Sanger data base, and many more are predicted to exist (3) .
miRNA biogenesis begins with a primary transcript that is generated by RNA polymerase II (see Ref. 4 for a review). Sequential processing events by the ribonuclease III enzymes Drosha and Dicer yield the mature miRNA species. Averaging 22 nucleotides long, the mature miRNA is loaded into the RNA-induced silencing complex where it directs translational suppression of target mRNAs. Several computational algorithms have been developed with the goal of defining the networks of genes regulated by miRNAs (see Ref. 5 for a review) . While the exact list of targets is not defined, the predicted targets extend to genes involved in a myriad of cellular processes. It is estimated that 30% of the human genome is under miRNA post-transcriptional regulation.
Despite the large number of candidate targets, the exact cellular pathways that are regulated by miRNAs are only beginning to be understood, particularly in mammals. miRNAs have been implicated in muscle development, hematopoietic differentiation, insulin regulation, and cell proliferation and apoptosis (see Ref. 6 for a review).
We recently reported that a polycistronic cluster of miRNAs, miR-17-92, can cooperate with c-Myc in a mouse model for lymphomagenesis (7) . This miRNA cluster has also been functionally implicated in colorectal carcinoma and lung carcinoma and has been defined as a common miRNA signature in several solid tumors (8 -10) . Expression of miR-17-92 is high in proliferating cells and is regulated in part by c-Myc itself (11) . In an effort to understand the transcriptional regulation of miR-17-92 and its connection to cell proliferation we characterized the promoter region of this miRNA cluster. Here we describe the promoter organization of miR-17-92 and demonstrate its direct regulation by E2F transcription factors.
EXPERIMENTAL PROCEDURES
Promoter Reporter Constructs-Promoter regions were amplified from human genomic DNA using the following primer sets: pro1353 5Ј, TTTCAGATTTGGCCTTTTATTTT; pro230 5Ј, GGAGGTCGGAAGTACTTTGTTT; pro1353 3Ј and pro230 3Ј, AGGAGAGCTTCGCGGAGGAG; thymidine kinase-1 (TK-1) 5Ј, AGGAACCTTGCTTGGGAAAC; TK-1 3Ј, ACGAACCCGAGTACTCTCCA. PCR products were cloned into the promoterless vector pGL3 Basic (Promega) using NheI/XhoI. Site directed mutagenesis was performed with the QuikChange kit (Stratagene) using the pro230/pGL3 vector as template and the following primer sets: E2F SITE SD1 5Ј, CG-ACCTGCGCCTTCGATCCACTTCGCGCCCTC; E2F SITE SD1 3Ј, GAGGGCGCGAAGTGGATCGAAGGCGCAGG-TCG; E2F SITE SD25Ј, CTTCGCGCCACTTCGATCCCTCG-GGCGTCCGG; E2F SITE SD23Ј, CCGGACGCCCGAGGGA-TCGAAGTGGCGCGAAG; TATA SD 5Ј, GGGCTTGTCCG-GAATTCCGTTGAGGCGG; TATA SD 3Ј, CCGCCTCAA-CGGAATTCCGGACAAGCCC.
Promoter activity was determined by co-transfection of the pGL3 promoter reporter (400 ng/well) with pRLSV40 (Renilla luciferase, Promega)(100 ng/well) into HEK-293 cells using FuGENE 6 (Roche Applied Science) and measurement of luciferase activity with the dual luciferase kit (Promega). Assays were performed in triplicate and standard deviations calculated. Activity was defined as Firefly/Renilla ratio, normalized to control vector transfection. For E2F transactivation assays, promoter activity was measured similarly with the following exceptions: NIH-3T3 were transfected with the pGL3 promoter reporter (400 ng/well) and pRLSV40 (200 ng/well), with or without E2F expression plasmids (400 ng/well), using Lipofectamine 2000 (Invitrogen). Activity was defined as Firefly/Renilla ratio normalized to activity in the absence of transfected E2F1.
5Ј-RACE Mapping of Transcript-HEK-293 cells were transiently transfected with the pro1353 vector and total RNA prepared (TRIzol, Invitrogen). RNA was decapped with tobacco acid phosphatase (Epicenter) and ligated to the synthetic RNA CGGUUUAAACGGUCCUUUAAA. cDNA was prepared (Superscript) and PCR performed using the following primers: RACE 5Ј, CGGTTTAAACGGTCCTTTAAA and RACE 3Ј, GTTCCATCTTCCAGCGGATA. PCR products were cloned into TOPO TA vector pCR2.1 and sequenced.
Chromatin Immunoprecipitation-HEK-293 cells (1 ϫ 10-cm plate/immunoprecipitation) were cross-linked/fixed in 1% formaldehyde for 10 min at room temperature. Cells were washed in PBS and the cross-linking halted with 125 mM glycine treatment for 5 min at room temperature. Cells were extracted in 300 l of SolA for 10 min on ice. Nuclei were recovered by centrifugation and extracted with 300 l of SolB for 20 min on ice and sonicated 5 times for 10 s each. Nuclear lysates were centrifuged, and the supernatant was diluted in 1 volume of buffer B and precleared with 60 l of protein-A-Sepharose plus 2 g of sheared salmon sperm DNA. Chromatin was captured with primary antibody at the following amounts: BD E2F1, 9 g (BD #554213); SC E2F1, 3 g (SC-193) ; SC E2F2, 6 g (SC-633); SC E2F3, 3 g (SC-878); glyceraldehyde-3-phosphate dehydrogenase, 2 g (Chemicon MAB374). After overnight capture the chromatin was precipitated with 20 l of protein-A-Sepharose, washed sequentially in TSE1, TSE2, TSE3, and TE. Chromatin was eluted with 250 l of buffer E for 15 min at room temperature. Eluate was adjusted with 4 l of 500 mM EDTA, 9 l of 1.0 M Tris, pH 7.6, 2 l of 10 mg/ml proteinase K, and 2 l of 10 mg/ml RNase A and incubated at 45°C for 1 h. Chromatin was decrosslinked at 65°C overnight. DNA was recovered by phenol extraction and amplified with the following primer sets: TK1 5Ј, ATGCCTGGACACAGGCTATC; TK1 3Ј, CAAATCTCCCGCCAGGTC; POLA5Ј, CCAAATCTTTTCC-CATCAGC; POLA3Ј, CTCGCCCCTATCTCACAGTC; 1792p1 5Ј, GAAGAAGGAGGTGCTCCTGA; 1792p1 3Ј, GCCCAGCT-GCATTTAGTAAGA; 1792p2 5Ј, ACCAGCTAGCGGAGGTC-GGAAGTACTTTGTTT; 1792p2 3Ј, ACCATCGAGAGGAGA-GCTTCGCGGAGGAG; 1792p3 5Ј, ATTCACCCACATGGTC-CTTC; 1792p3 3Ј, GCCTGCGCTTTACTACGAC.
Buffers-The following buffers were used: SolA, 10 mM Hepes, pH 7.9, 0.5% Nonidet P-40, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, protease inhibitors; SolB, 20 mM Hepes, pH 7.9, 25% glycerol, 0.5% Nonidet P-40, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, protease inhibitors; Buffer B, 1% Triton X-100, 2 mM EDTA, 50 mM NaCl, 20 mM Tris-HCl, pH 7.9, protease inhibitors; TSE1, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-Cl, pH 8.1; TSE2, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-Cl, pH 8.1; TSE3, 0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-Cl, pH 8.1; Buffer E, 1% SDS, 0.1 M NaHCO 3 .
RESULTS AND DISCUSSION
The miR-17-92 cluster is comprised of miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1, all of which are housed in the expressed sequence tag (EST) chr13orf25 (see Fig. 1A ). The sequence upstream of the putative transcriptional start site is highly conserved across vertebrate genomes and contains an extensive CpG island, indicative of a core promoter region. In an effort to identify the true transcriptional start site we employed RACE cloning of the 5Ј end. This was unsuccessful due to the extreme GC content of the 5Ј end of the RNA. As an alternative strategy we cloned a 1353-nucleotide genomic region upstream of the chr13orf25 transcript, overlapping the 5Ј end of the EST (construct pro1353, Fig. 1A ). This region conferred strong transcriptional activity to a promoterless luciferase reporter vector (Fig. 1B) . A smaller promoter region that contained the minimal conserved region had less activity, presumably due to removal of positive cis-elements (construct pro230, Fig. 1, A and B) . RACE cloning of the pro1353/luciferase fusion was successful, enabling us to map the preferred start site 134 nucleotides upstream of the 5Ј end of the EST (Fig. 1A) . We believe this is the true start site, since it resides within a highly conserved region, in contrast to the terminus of the EST, which is non-conserved. The identified start site conforms to the initiator consensus sequence YYANTY, where the adenine is the start of transcription. In addition, there is a nonconsensus TATA box Ϫ32 from the start site, which is within the preferred location (Ϫ29 to Ϫ32, measured from the first thymine) (12, 13) . The TATA box matches the sequence of the SV-40 early gene TATA box, which does not bind TBP but is still important for transcriptional activity at the downstream start site (14, 15) . Similarly, the miR-17-92 TATA box is important for transcription, as site-directed mutation of the sequence attenuates transcriptional activity (Fig. 1B) .
Expression of miR-17-92 has been correlated with proliferating cells. Therefore, we hypothesized that its promoter would contain binding sites for transcription factors with established roles in cell proliferation. Analysis of the promoter revealed two conserved E2F binding sites downstream of the start site (Fig.  1A) . We tested the function of these sites by cotransfection of the pro230 and pro1353 promoter reporter constructs with an expression plasmid that directs expression of human E2F1. Both reporters were strongly transactivated by E2F1 (Fig. 2A) . Shown for comparison is a reporter for TK-1, a promoter known to be E2F regulated. The E2F1 point mutant L132E, which lacks DNA binding activity, had a minimal effect on the reporter. E2F1 transactivates many genes, including other transcription factors such as c-Myc. To confirm that E2F-mediated regulation of miR-17-92 is direct we mutated the E2F binding sites from the pro230 reporter by site-directed mutagenesis (Fig. 2B) . Removal of either site essentially abolished transactivation by E2F1 (Fig. 2C) .
Nine E2F family members have been described: E2F1, E2F2, and E2F3a, which are transcriptional activators, and E2F3b to E2F8, which are transcriptional repressors (see Ref. 16 for a review). The essential role of E2Fs in the progression of the cell cycle is well known. A large number of S phase genes, including thymidine kinase, DNA polymerase ␣, and Cyclins E and A, are transactivated by E2Fs. Loss of all three activating E2Fs leads to a failure of S phase entry (17) . Loss of a single activating E2F does not lead to cell cycle defects due to partial redundancy; however, there are specialized roles for individual family mem- bers (18) . In particular, E2Fs promote apoptosis in some cellular contexts, and this is dependent on E2F1 activity. Mice lacking E2F1 are tumor prone as a consequence, while mice lacking E2F3 are not (19 -21) . Similarly, mouse embryo fibroblasts that are deficient for E2F1 are resistant to apoptosis, even in the presence of elevated E2F3 (22) .
While our data implicates E2F1 in the regulation of miR-17-92, it is probable that isoform specificity is lost as a consequence of overexpression. To identify the endogenous family member that occupies the miR-17-92 promoter we employed chromatin immunoprecipitation (Fig. 3) . As controls we analyzed the DNA polymerase alpha promoter, which is occupied by all three activating E2Fs, and TK-1, which is occupied predominantly by E2F3 (23) . Three independent primer sets flanking the miR-17-92 start site were used to detect E2F occupancy. All three primer sets detected E2F3 as the isoform predominantly associated with the promoter region. While this data does not rule out E2F1 and E2F2 association with other regions of the promoter, it confirms the role of E2F3 in the regulation of miR-17-92.
These data allow us to develop a model for miR-17-92 function (Fig. 4) . Proliferative signals that converge on the Retinoblastoma gene product lead to activity of E2F transcription factors (24) . In addition to induction of genes essential for S phase entry, E2Fs transactivate the oncogenic miRNAs miR-17-92. The exact cellular role of miR-17-92 is unknown, but lymphomas that express these miRNAs at a high level have reduced apoptosis (7) . E2F1 is a validated target of miR-17 and miR-20 (11) . Therefore, elevation of miR-17-92 would lead to decreased E2F1 protein and would thus attenuate E2F induced apoptosis. Since E2F3 is the predominant isoform that regulates miR-17-92 in cells, the targeting of E2F1 would not produce negative feedback but would rather promote E2F3 proliferative signal rather than E2F1 apoptotic signal. Our data also provide a mechanism for elevated miR-17-92 in proliferating cells. E2F activity is periodic with the cell cycle, reaching a peak during S phase (for E2F1-3) (24). We do not expect miR-17-92 to follow this periodicity, since the half-life of mature miRNAs is much longer than the typical cell cycle. 4 Rather, cycling cells would have elevated steady state levels of miR-17-92 due to the periodic burst of E2F activity during S phase, while quiescent cells would have reduced miR-17-92 levels. In a parallel pathway, miR-17-92 is regulated by c-Myc (11). E2F and Myc transactivate each other, providing a complex regulatory signal for miR-17-92 expression.
